Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for their
growth or by blocking blood flow to the tumor. Interferon alfa may interfere with the growth
of tumor cells and slow the growth of kidney cancer. Sorafenib may help interferon alfa kill
more tumor cells by making tumor cells more sensitive to the drug. Giving sorafenib together
with interferon alfa may kill more tumor cells. This phase II trial is studying how well
giving sorafenib with interferon alfa works in treating patients with locally advanced or
metastatic kidney cancer.